China
Africa
Explore chapters and articles related to this topic
The Bioprocessing Industry—An Introduction
Published in Sarfaraz K. Niazi, Disposable Bioprocessing Systems, 2016
Wyeth invested US$1.8 B in its Grange Castle facility, where site development work began in October 2002. The campus comprises three separate facilities: a drug development unit, a drug substance unit, and a drug production facility. These facilities went into production on a phased basis by 2009. Products that are manufactured at the new biotech facility include Enbrel (etanercept), Prevenar (pneumococcal conjugate vaccine), antihemophilic factor VIII, recombinant human bone morphogenetic protein (rhBMP-2), Tygacil (tigecycline IV), and Relistor (methylnaltrexone bromide). Construction required more than 15,000 tons of structural steel, 160,000 ft of process piping, 2,400 items of equipment, 7,587 engineering drawings, and 1,200 specific validation protocols. Zenith Technology was responsible for the validation of all automated systems. This new facility is the largest fully integrated facility ever built in a single phase. In March 2007, the Wyeth Corporation announced a further $32 million investment at the Grange Castle site, which would include the construction of an additional 6,000 m2 of R&D laboratory space. This will then take the total laboratory space available at the site to 8,500 m2.
Forecasting the demand of mobile clinic services at vulnerable communities based on integrated multi-source data
Published in IISE Transactions on Healthcare Systems Engineering, 2021
Bilal Majeed, Jiming Peng, Ang Li, Ying Lin, Rigoberto I Delgado
The school-level data is extracted from the HISD annual reports of immunization that provide the aggregated records for different vaccinations in pre-kindergarten, kindergarten, and seventh grade (HISD Annual Report of Immunization Status, 2016–2018) and the campus demographic reports (CDR) that provides various characteristics on enrolled student populations (HISD Campus Demogrpahic Reports, 2016–2018). Schools require the proof of immunization compliance at the pre-kindergarten, kindergarten and seventh grade level: hepatitis-A (HepA), hepatitis-B (HepB), measles, mumps and rubella (MMR), polio and varicella (VAR) vaccinations are reviewed at all three grade levels; diphtheria, tetanus toxoids and whole-cell pertussis (DTP) vaccinations are reviewed at pre-kindergarten and kindergarten level; haemophilus influenza type b (Hib), measles and pneumococcal conjugate vaccine (PCV) are reviewed at pre-kindergarten level; and meningitis, tetanus and diphtheria Vaccine (TD), tetanus, diphtheria, and acellular pertussis, diphtheria and acellular pertussis vaccine (Tdap) are reviewed at grade seventh only. Students who are not in compliance as per the Texas minimum state vaccine requirements are regarded as “delinquent” (HISD Annual Report of Immunization Status, 2016–2018). We observed varying delinquencies for different grade levels, however, there exist strong correlations between the delinquencies for different vaccines at a particular grade level. The HISD campus demographic reports included very limited information on student populations such as racial demographics and economic background. Further, this information is only available in aggregate form as details for individual students are protected by the Family Educational Rights and Privacy Act (FERPA).